Your browser doesn't support javascript.
Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses.
Jia, Janice Zhirong; Tan, Chee Wah; Cheng, Samuel M S; Gu, Haogao; Yeoh, Aileen Ying Yan; Mok, Chris Ka Pun; Wang, Yanqun; Zhao, Jincun; Leung, Nancy H L; Cowling, Benjamin J; Poon, Leo L M; Hui, David S C; Wang, Linfa; Peiris, Malik; Valkenburg, Sophie A.
  • Jia JZ; HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Tan CW; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Cheng SMS; School of Public Health, The University of Hong Kong, Hong Kong SAR, China.
  • Gu H; School of Public Health, The University of Hong Kong, Hong Kong SAR, China.
  • Yeoh AYY; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Mok CKP; The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Wang Y; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Zhao J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Leung NHL; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Cowling BJ; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Poon LLM; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Hui DSC; HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Wang L; School of Public Health, The University of Hong Kong, Hong Kong SAR, China.
  • Peiris M; Centre for Immunology and Infection (C2I), Hong Kong Science Park, Hong Kong SAR, China.
  • Valkenburg SA; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Nat Commun ; 13(1): 6285, 2022 Oct 21.
Article in English | MEDLINE | ID: covidwho-2087205
ABSTRACT
Vaccines that are broadly cross-protective against current and future SARS-CoV-2 variants of concern (VoC) or across the sarbecoviruses subgenus remain a priority for public health. Virus neutralization is the best available correlate of protection. To define the magnitude and breadth of cross-neutralization in individuals with different exposure to SARS-CoV-2 infection and vaccination, we here use a multiplex surrogate neutralization assay based on virus spike receptor binding domains of multiple SARS-CoV-2 VoC, as well as related bat and pangolin viruses. We include sera from cohorts of individuals vaccinated with two or three doses of mRNA (BNT162b2) or inactivated SARS-CoV-2 (Coronavac or Sinopharm) vaccines with or without a history of previous SARS-CoV-2 or SARS-CoV-1 infection. SARS-CoV-2 or SARS-CoV-1 infection followed by BNT162b2 vaccine, Omicron BA.2 breakthrough infection following BNT162b2 vaccine or a third dose of BNT162b2 following two doses of BNT162b2 or Coronavac elicit the highest and broadest neutralization across VoCs. For both breadth and magnitude of neutralization across all sarbecoviruses, those infected with SARS-CoV-1 immunized with BNT162b2 outperform all other combinations of infection and/or vaccination. These data may inform vaccine design strategies for generating broadly neutralizing antibodies to SARS-CoV-2 variants or across the sarbecovirus subgenus.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-34038-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-34038-6